Attention: You are using an outdated browser, device or you do not have the latest version of JavaScript downloaded and so this website may not work as expected. Please download the latest software or switch device to avoid further issues.

News > Community news > Crick spinout to begin first-in-human clinical study for leukaemia

Crick spinout to begin first-in-human clinical study for leukaemia

GammaDelta Therapeutics has received Investigational New Drug approval from the US FDA for their GDX012 cell therapy to be investigated as a treatment for blood cancers. 
7 Jun 2021
United States of America
Community news

Featured

Clinicians

To view this News Article please log in or create a profile

Similar stories

Congratulations are in order for Julian Downward and his lab, who have been awarded $1m over three years from the Novartis Global Scholars Program (NGSP) to study drug resistance i… More...

.

Charlie has received the award for his discoveries in cancer genetics and evolution, leading to insights into how tumour… More...

.

The grant will support Charlie Swanton from the Cancer Evolution and Genome Instability Laboratory and Sherene Loi from … More...

Crick postdoc Catherine Hurd has been awarded a Wellcome Trust Early Career Award. She tells us about her research at th… More...

Pontus Skoglund, Group Leader of the Crick Ancient Genomics Laboratory, has been awarded a €2m Consolidator Grant from t… More...

Have your say

 
image

Contact us

The Francis Crick Institute
1 Midland Road
London
NW1 1AT

connect@crick.ac.uk


This website is powered by
ToucanTech